Correspondence 0001104659-24-081489 from MetaVia Inc. (MTVA)
MetaVia Inc.
Date: July 22, 2024 · CIK: 0001638287 · Accession: 0001104659-24-081489
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280865
Letter
Re: NeuroBo Pharmaceuticals, Inc.
July 22, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Jimmy McNamara
Registration Statement on Form S-1
File No. 333-280865
Acceleration Request
Requested Date: July 24,
Requested Time: 5:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, NeuroBo Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-1 (File No. 333-280865) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Phillip Torrence and Josh Damm of Honigman LLP, counsel to the Company, to make such request on its behalf.
Please confirm the effectiveness of the Registration Statement with Phillip Torrence of Honigman LLP by telephone at (269) 337-7702 or Josh Damm of Honigman LLP by telephone at (313) 465-7714.
Sincerely,
NeuroBo Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
July 22, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Jimmy McNamara
Re:
NeuroBo Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-280865
Acceleration Request
Requested Date: July 24,
2024
Requested Time: 5:00
P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461
under the Securities Act of 1933, as amended, NeuroBo Pharmaceuticals, Inc. (the “Company”) hereby respectfully
requests that the above-referenced Registration Statement on Form S-1 (File No. 333-280865) (the “Registration Statement”)
be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable
thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of
Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Phillip Torrence and Josh Damm of
Honigman LLP, counsel to the Company, to make such request on its behalf.
Please confirm the effectiveness
of the Registration Statement with Phillip Torrence of Honigman LLP by telephone at (269) 337-7702 or Josh Damm of Honigman LLP by telephone
at (313) 465-7714.
Sincerely,
NeuroBo Pharmaceuticals, Inc.
/s/ Hyung Heon Kim
Hyung Heon Kim
President, Chief Executive Officer and Director
cc:
Marshall Woodworth, Chief Financial Officer
NeuroBo Pharmaceuticals, Inc.
Phillip D. Torrence, Esq.
Joshua W. Damm, Esq.
Samuel Katz, Esq.
Honigman LLP
NeuroBo Pharmaceuticals, Inc.
545 Concord Avenue, Suite 210
Cambridge, MA 02138
857.702.9600